Belite Bio, Inc (BLTE)

Market Cap	6.64B +203.8%
Revenue (ttm)	n/a
Net Income	-77.61M
EPS	-2.31
Shares Out	39.34M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,455
Open	170.38
Previous Close	171.17
Day's Range	166.56 - 170.62
52-Week Range	49.00 - 200.00
Beta	-1.22
Analysts	Strong Buy
Price Target	198.00 (+17.33%)
Earnings Date	May 12, 2026

About BLTE

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding pr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 29, 2022
• Employees: 25
• Stock Exchange: NASDAQ
• Ticker Symbol: BLTE
• Website: https://www.belitebio.com

Analyst Summary

According to 7 analysts, the average rating for BLTE stock is "Strong Buy." The 12-month stock price target is $198.0, which is an increase of 17.33% from the latest price.

Price Target

$198.0

(17.33% upside)

Analyst Consensus: Strong Buy